Ritocom tablet

GetHIVTreatment sells Ritocom 50 mg/200 mg Tablet for resellers and stockists looking to source this combination antiretroviral product. Pricing is available on the product listing page, where bulk order quantities are reflected in the per-strip cost. Buyers ordering in volume will find Ritocom 50 mg/200 mg Tablet competitively placed within the generic antiretroviral wholesale market.

Product information

Ritocom 50 mg/200 mg Tablet contains two active ingredients: Ritonavir 50 mg and Lopinavir 200 mg. Each tablet delivers a fixed-dose combination of both compounds in a single unit. The product is manufactured by Hetero Drugs. This is a solid oral tablet intended for the treatment of human immunodeficiency virus type 1 infection in adults. Ritonavir 50 mg + Lopinavir 200 mg is the standard fixed-dose pairing used across generic antiretroviral supply chains globally.

Condition This Product Treats

Ritocom 50 mg/200 mg Tablet is used for the treatment of human immunodeficiency virus type 1 infection. It is used as part of combination antiretroviral therapy in adult patients. The product covers ongoing viral suppression and is a widely stocked line in HIV treatment supply programs. Demand is stable. Buyers reorder consistently.

Available Strengths and Pack Sizes

The available strength of this product is the fixed combination of Ritonavir 50 mg and Lopinavir 200 mg per tablet. Each tablet contains both actives in this ratio. Pack size details are listed on the GetHIVTreatment product page, where strip counts and carton quantities are shown for wholesale and reseller ordering. Buyers sourcing this in bulk should confirm available pack configurations at the time of ordering. The Ritonavir 50 mg plus Lopinavir 200 mg combination is the single strength variant available in this line.

How It Works

Lopinavir works by blocking the action of the human immunodeficiency virus protease enzyme. This enzyme is responsible for cutting long viral proteins into the smaller functional pieces the virus needs to produce new infectious particles. When protease blocking occurs, the virus assembles non-functional particles that cannot infect new cells. Ritonavir does not contribute primary antiviral activity at this dose level. Instead, the body converts it after absorption into a compound that slows the breakdown of Lopinavir by blocking cytochrome P450 3A4, a liver enzyme responsible for metabolising many drugs.

This blocking effect keeps Lopinavir at higher concentrations in the blood for longer periods. The mechanism is well understood. The result is stronger and more sustained antiviral activity than Lopinavir would produce without it.

Side Effect

The side effect of Ritocom 50 mg/200 mg Tablet is typical of protease inhibitor-based antiretroviral therapy. Gastrointestinal effects are the most commonly reported, including nausea, diarrhoea, and abdominal discomfort. Raised triglyceride and cholesterol levels are associated with this drug class and appear in the profile of this combination.

Liver enzyme elevation has been reported with protease inhibitor use. Heart rhythm changes are noted in the class profile and are associated with Lopinavir specifically. Fatigue and headache also appear in reported adverse event data. The profile is well documented across clinical and post-market sources. No unusual or unexpected signals fall outside what is typical of this drug class.

Shelf Life and Storage Requirements

Ritocom 50 mg/200 mg Tablet should be stored at controlled room temperature, away from direct heat, moisture, and sunlight. Tablets in blister or foil packaging should be kept in their original packaging until dispensed or distributed. Standard pharmaceutical warehouse storage conditions apply. Buyers holding stock for resale should verify the manufacturing date and shelf life on each carton at the time of receipt. Storage below 25 degrees Celsius is generally recommended for solid oral antiretroviral tablets of this class. Cold chain is not required for this product under normal stock conditions.

Why Buyers Choose This Product

Ritonavir 50 mg plus Lopinavir 200 mg in a fixed-dose combination tablet is one of the most consistently demanded lines in the generic antiretroviral wholesale market. The fixed-dose format reduces handling complexity for distributors and simplifies stock management at the reseller level. Hetero Healthcare manufactures this combination to standard generic pharmaceutical specifications, supporting reliable supply for buyers operating in regulated and semi-regulated markets. Resellers stocking HIV treatment lines include this product as a core item. It moves. The combination antiretroviral category shows no signs of reduced demand across wholesale channels.